A Pilot Descriptive Canadian, Multicenter, Open-label, Randomized Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus Patients
Phase of Trial: Phase III
Latest Information Update: 17 Oct 2017
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms TITRATION
- Sponsors Sanofi
- 17 Oct 2017 According to a Sanofi media release, this study was published in Canadian Journal of Diabetes.
- 16 Sep 2016 Results presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes
- 25 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.